Correlation Between NYSE Composite and Virpax Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both NYSE Composite and Virpax Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NYSE Composite and Virpax Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between NYSE Composite and Virpax Pharmaceuticals, you can compare the effects of market volatilities on NYSE Composite and Virpax Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NYSE Composite with a short position of Virpax Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of NYSE Composite and Virpax Pharmaceuticals.
Diversification Opportunities for NYSE Composite and Virpax Pharmaceuticals
-0.65 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between NYSE and Virpax is -0.65. Overlapping area represents the amount of risk that can be diversified away by holding NYSE Composite and Virpax Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Virpax Pharmaceuticals and NYSE Composite is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NYSE Composite are associated (or correlated) with Virpax Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Virpax Pharmaceuticals has no effect on the direction of NYSE Composite i.e., NYSE Composite and Virpax Pharmaceuticals go up and down completely randomly.
Pair Corralation between NYSE Composite and Virpax Pharmaceuticals
Assuming the 90 days trading horizon NYSE Composite is expected to generate 0.08 times more return on investment than Virpax Pharmaceuticals. However, NYSE Composite is 12.72 times less risky than Virpax Pharmaceuticals. It trades about 0.08 of its potential returns per unit of risk. Virpax Pharmaceuticals is currently generating about -0.01 per unit of risk. If you would invest 1,547,479 in NYSE Composite on August 24, 2024 and sell it today you would earn a total of 464,866 from holding NYSE Composite or generate 30.04% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
NYSE Composite vs. Virpax Pharmaceuticals
Performance |
| Timeline |
NYSE Composite and Virpax Pharmaceuticals Volatility Contrast
Predicted Return Density |
| Returns |
NYSE Composite
Pair trading matchups for NYSE Composite
Virpax Pharmaceuticals
Pair trading matchups for Virpax Pharmaceuticals
Pair Trading with NYSE Composite and Virpax Pharmaceuticals
The main advantage of trading using opposite NYSE Composite and Virpax Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NYSE Composite position performs unexpectedly, Virpax Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Virpax Pharmaceuticals will offset losses from the drop in Virpax Pharmaceuticals' long position.| NYSE Composite vs. Awilco Drilling PLC | NYSE Composite vs. AKITA Drilling | NYSE Composite vs. SunOpta | NYSE Composite vs. Delek Drilling |
| Virpax Pharmaceuticals vs. Revelation Biosciences | Virpax Pharmaceuticals vs. Palisade Bio | Virpax Pharmaceuticals vs. Virax Biolabs Group | Virpax Pharmaceuticals vs. Quoin Pharmaceuticals Ltd |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Complementary Tools
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |